Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

DARZALEX FASPRO® is now the first and only subcutaneous anti-CD38 monoclonal antibody approved in combination with pomalidomide and dexamethasone HORSHAM, Pa., July 12, 2021 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Co... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, DARZALEX FASPRO®, daratumumab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news